Despite Werewolf Therapeutics' stock surge, its modest P/S r...
Despite Werewolf Therapeutics' stock surge, its modest P/S ratio is justified due to inconsistent revenue growth and forecasted contraction. The weak outlook could continue to impact the share price.
Werewolf Therapeutics, Inc.'s (NASDAQ:HOWL) Shares Bounce 27% But Its Business Still Trails The Industry
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment